148 related articles for article (PubMed ID: 32483162)
21. microRNA-431 as a Chemosensitizer and Potentiator of Drug Activity in Adrenocortical Carcinoma.
Kwok GTY; Zhao JT; Glover AR; Gill AJ; Clifton-Bligh R; Robinson BG; Ip JCY; Sidhu SB
Oncologist; 2019 Jun; 24(6):e241-e250. PubMed ID: 30918109
[TBL] [Abstract][Full Text] [Related]
22. Metformin as a new anti-cancer drug in adrenocortical carcinoma.
Poli G; Cantini G; Armignacco R; Fucci R; Santi R; Canu L; Nesi G; Mannelli M; Luconi M
Oncotarget; 2016 Aug; 7(31):49636-49648. PubMed ID: 27391065
[TBL] [Abstract][Full Text] [Related]
23. Targeting estrogen receptor-α reduces adrenocortical cancer (ACC) cell growth in vitro and in vivo: potential therapeutic role of selective estrogen receptor modulators (SERMs) for ACC treatment.
Sirianni R; Zolea F; Chimento A; Ruggiero C; Cerquetti L; Fallo F; Pilon C; Arnaldi G; Carpinelli G; Stigliano A; Pezzi V
J Clin Endocrinol Metab; 2012 Dec; 97(12):E2238-50. PubMed ID: 23074235
[TBL] [Abstract][Full Text] [Related]
24. Targeted Molecular Analysis in Adrenocortical Carcinomas: A Strategy Toward Improved Personalized Prognostication.
Lippert J; Appenzeller S; Liang R; Sbiera S; Kircher S; Altieri B; Nanda I; Weigand I; Gehrig A; Steinhauer S; Riemens RJM; Rosenwald A; Müller CR; Kroiss M; Rost S; Fassnacht M; Ronchi CL
J Clin Endocrinol Metab; 2018 Dec; 103(12):4511-4523. PubMed ID: 30113656
[TBL] [Abstract][Full Text] [Related]
25. The next generation of therapies for adrenocortical cancers.
Kirschner LS
Trends Endocrinol Metab; 2012 Jul; 23(7):343-50. PubMed ID: 22626690
[TBL] [Abstract][Full Text] [Related]
26. New targeted therapies for adrenocortical carcinomas.
Manso J; Pezzani R
Minerva Endocrinol; 2019 Mar; 44(1):70-81. PubMed ID: 29808641
[TBL] [Abstract][Full Text] [Related]
27. Targeting heterogeneity of adrenocortical carcinoma: Evaluation and extension of preclinical tumor models to improve clinical translation.
Hantel C; Shapiro I; Poli G; Chiapponi C; Bidlingmaier M; Reincke M; Luconi M; Jung S; Beuschlein F
Oncotarget; 2016 Nov; 7(48):79292-79304. PubMed ID: 27764813
[TBL] [Abstract][Full Text] [Related]
28. Emerging drugs for adrenocortical carcinoma.
Berruti A; Ferrero A; Sperone P; Daffara F; Reimondo G; Papotti M; Dogliotti L; Angeli A; Terzolo M
Expert Opin Emerg Drugs; 2008 Sep; 13(3):497-509. PubMed ID: 18764725
[TBL] [Abstract][Full Text] [Related]
29. New insights and future perspectives in the therapeutic strategy of adrenocortical carcinoma (Review).
Stigliano A; Cerquetti L; Lardo P; Petrangeli E; Toscano V
Oncol Rep; 2017 Mar; 37(3):1301-1311. PubMed ID: 28184938
[TBL] [Abstract][Full Text] [Related]
30. Complete Responses to Mitotane in Metastatic Adrenocortical Carcinoma-A New Look at an Old Drug.
Reidy-Lagunes DL; Lung B; Untch BR; Raj N; Hrabovsky A; Kelly C; Gerst S; Katz S; Kampel L; Chou J; Gopalan A; Saltz LB
Oncologist; 2017 Sep; 22(9):1102-1106. PubMed ID: 28559412
[TBL] [Abstract][Full Text] [Related]
31. An Interesting Case of Hepatic Adrenocortical Carcinoma.
Permana H; Darmawan G; Ritonga E; Kusumawati M; Miftahurachman M; Soetedjo NN
Acta Med Indones; 2018 Jul; 50(3):257-259. PubMed ID: 30333277
[TBL] [Abstract][Full Text] [Related]
32. Potentiation of mitotane action by rosuvastatin: New insights for adrenocortical carcinoma management.
Boulate G; Amazit L; Naman A; Seck A; Paci A; Lombes A; Pussard E; Baudin E; Lombes M; Hescot S
Int J Oncol; 2019 Jun; 54(6):2149-2156. PubMed ID: 30942448
[TBL] [Abstract][Full Text] [Related]
33. New perspectives for mitotane treatment of adrenocortical carcinoma.
Puglisi S; Calabrese A; Basile V; Pia A; Reimondo G; Perotti P; Terzolo M
Best Pract Res Clin Endocrinol Metab; 2020 May; 34(3):101415. PubMed ID: 32179008
[TBL] [Abstract][Full Text] [Related]
34. Targeted Assessment of
Mohan DR; Lerario AM; Else T; Mukherjee B; Almeida MQ; Vinco M; Rege J; Mariani BMP; Zerbini MCN; Mendonca BB; Latronico AC; Marie SKN; Rainey WE; Giordano TJ; Fragoso MCBV; Hammer GD
Clin Cancer Res; 2019 Jun; 25(11):3276-3288. PubMed ID: 30770352
[TBL] [Abstract][Full Text] [Related]
35. Chloroquine enhances the efficacy of cisplatin by suppressing autophagy in human adrenocortical carcinoma treatment.
Qin L; Xu T; Xia L; Wang X; Zhang X; Zhang X; Zhu Z; Zhong S; Wang C; Shen Z
Drug Des Devel Ther; 2016; 10():1035-45. PubMed ID: 27022243
[TBL] [Abstract][Full Text] [Related]
36. Adrenocortical Carcinoma: A Clinician's Perspective.
Elfiky A
Surg Pathol Clin; 2015 Dec; 8(4):751-4. PubMed ID: 26612225
[TBL] [Abstract][Full Text] [Related]
37. Computational drug repositioning for rare diseases in the era of precision medicine.
Delavan B; Roberts R; Huang R; Bao W; Tong W; Liu Z
Drug Discov Today; 2018 Feb; 23(2):382-394. PubMed ID: 29055182
[TBL] [Abstract][Full Text] [Related]
38. Risk of adrenocortical carcinoma in adrenal tumours greater than 8 cm.
Abdel-Aziz TE; Rajeev P; Sadler G; Weaver A; Mihai R
World J Surg; 2015 May; 39(5):1268-73. PubMed ID: 25526921
[TBL] [Abstract][Full Text] [Related]
39. Lack of long-lasting effects of mitotane adjuvant therapy in a mouse xenograft model of adrenocortical carcinoma.
Doghman M; Lalli E
Mol Cell Endocrinol; 2013 Dec; 381(1-2):66-9. PubMed ID: 23906534
[TBL] [Abstract][Full Text] [Related]
40. Xenograft models for preclinical drug testing: implications for adrenocortical cancer.
Luconi M; Mannelli M
Mol Cell Endocrinol; 2012 Mar; 351(1):71-7. PubMed ID: 22056412
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]